Acurx Pharmaceuticals(us:ACXP)
0.3793
-2.74%
Updated on 2025-04-02
Open:0.3960
Close:0.3793
High:0.3960
Low:0.3750
Prev Close:0.3900
Volume:151524.00
Turnover:57996.09
Turnover Ratio:0.69%
Shares:22.04M
MarketCap:8.36M
| Date | Total | Total Shares | Total Ratio | New | Increased | Decreased |
|---|---|---|---|---|---|---|
| 2024-06-30 | 1 | 19000 | 0.12% | 0 | 1 | 0 |
| 2024-03-31 | 31 | 1248713 | 7.92% | 8 | 7 | 10 |
| 2023-12-31 | 30 | 1092515 | 7.55% | 12 | 8 | 8 |
| 2023-09-30 | 18 | 873725 | 6.72% | 5 | 5 | 5 |
| 2023-06-30 | 14 | 1466385 | 11.28% | 3 | 6 | 3 |
| 2023-03-31 | 13 | 519936 | 4.45% | 1 | 4 | 5 |
| 2022-12-31 | 15 | 1304724 | 11.22% | 2 | 3 | 6 |
| 2022-09-30 | 15 | 1522316 | 13.13% | 4 | 5 | 3 |
| date | orgName | total | ratio | changeShares | changeRatio |
|---|---|---|---|---|---|
| 2024-03-31 | Vanguard Group Inc | 491687 | 3.12% | 85300 | 20.99% |
| 2024-03-31 | Prospect Financial Services Llc | 272850 | 1.73% | 17700 | 6.94% |
| 2024-03-31 | Geode Capital Management, Llc | 116352 | 0.74% | 4220 | 3.76% |
| 2024-03-31 | Osaic Holdings, Inc. | 57250 | 0.36% | 0 | |
| 2024-03-31 | State Street Corp | 43466 | 0.28% | 14900 | 52.16% |
| 2024-03-31 | Lpl Financial Llc | 40235 | 0.26% | 26555 | 194.12% |
| 2024-03-31 | Susquehanna International Group, Llp | 37438 | 0.24% | -16115 | -30.09% |
| 2024-03-31 | Morgan Stanley | 26401 | 0.17% | 10200 | 62.96% |
| 2024-03-31 | Blackrock Inc. | 18688 | 0.12% | -44438 | -70.40% |
| 2024-03-31 | Td Waterhouse Canada Inc. | 18656 | 0.12% | 0 |
About
Acurx Pharmaceuticals, Inc. operates as a clinical stage biopharmaceutical company, which engages in developing new antibiotics for infections caused by bacteria listed as priority pathogens. Its approach is to develop antibiotic candidates that target the DNA polymerase IIIC enzyme. Its research and development pipeline includes early-stage antibiotic candidates that target other Gram-positive bacteria, including Methicillin-Resistant Staphylococcus aureus, Vancomycin-Resistant Enterococcus and Penicillin-Resistant Streptococcus pneumoniae. The company was founded by David P. Luci, Robert G. Shawah and Robert J. DeLuccia in July 2017 and is headquartered in New York, NY.
Address:259 Liberty Avenue,Staten Island
Website:http://www.acurxpharma.com
Market Movers